AG真人官方

STOCK TITAN
  1. Home
  2. Sec-filings
  3. IDXX
  4. [Form 4] Idexx Laboratories Inc Insider Trading Activity

[Form 4] Idexx Laboratories Inc Insider Trading Activity

Filing Impact
(High)
Filing Sentiment
(Very Negative)
Form Type
4
Rhea-AI Filing Summary

Jonathan Jay Mazelsky, President and CEO and a director of IDEXX Laboratories (IDXX), reported a series of transactions dated 08/06/2025. He acquired 29,260 shares by exercising non-qualified stock options at an exercise price of $67.85 per share and sold a matching total of 29,260 common shares the same day in multiple tranches at reported weighted-average prices between $626.9024 and $639.3718 per share. The reported sales reduced his direct holdings from 112,571.3016 shares to 83,311.3016 shares. Based on the reported quantities and prices, the aggregate gross proceeds from the sales are approximately $18.49 million. The filing also references an option grant to buy 41,260 shares that became exercisable in five annual installments beginning 02/14/2017.

Jonathan Jay Mazelsky, presidente e CEO nonch茅 membro del consiglio di IDEXX Laboratories (IDXX), ha comunicato una serie di operazioni in data 08/06/2025. Ha acquisito 29,260 azioni esercitando opzioni su azioni non qualificate a un prezzo di esercizio di $67.85 per azione e nello stesso giorno ha venduto un totale corrispondente di 29,260 azioni ordinarie in pi霉 tranche a prezzi medi ponderati segnalati compresi tra $626.9024 e $639.3718 per azione. Le vendite riportate hanno ridotto le sue partecipazioni dirette da 112,571.3016 azioni a 83,311.3016 azioni. Sulla base delle quantit脿 e dei prezzi indicati, i proventi lordi aggregati delle vendite sono circa $18.49 milioni. Il deposito fa inoltre riferimento a una concessione di opzione per acquistare 41,260 azioni divenuta esercitabile in cinque rate annuali a partire dal 02/14/2017.

Jonathan Jay Mazelsky, presidente y director ejecutivo y miembro del consejo de IDEXX Laboratories (IDXX), inform贸 una serie de operaciones con fecha 08/06/2025. Adquiri贸 29,260 acciones al ejercer opciones sobre acciones no calificadas a un precio de ejercicio de $67.85 por acci贸n y ese mismo d铆a vendi贸 un total coincidente de 29,260 acciones ordinarias en varias tramos a precios medios ponderados reportados entre $626.9024 y $639.3718 por acci贸n. Las ventas notificadas redujeron sus tenencias directas de 112,571.3016 acciones a 83,311.3016 acciones. Seg煤n las cantidades y precios informados, los ingresos brutos agregados de las ventas ascienden aproximadamente a $18.49 millones. La presentaci贸n tambi茅n hace referencia a una concesi贸n de opciones para comprar 41,260 acciones que se volvi贸 ejercitable en cinco cuotas anuales a partir del 02/14/2017.

Jonathan Jay Mazelsky電� IDEXX Laboratories (IDXX)鞚� 須岇灔 瓴� CEO鞚挫瀽 鞚挫偓搿滌劀 08/06/2025鞚检瀽 鞚茧牗鞚� 瓯半灅毳� 氤搓碃頄堨姷雼堧嫟. 攴鸽姅 牍勳瀽瓴� 鞀ろ啞鞓奠厴鞚� 頄夓偓頃橃棳 欤茧嫻 頄夓偓臧�瓴� $67.85搿� 29,260欤茧ゼ 旆摑頄堨溂氅�, 臧欖潃 雮� 霃欖澕頃� 齑濌硠鞚� 氤错喌欤� 29,260欤茧ゼ 鞐煬 韸鸽灉旃橂 臧侁皝 氤搓碃霅� 臧�欷戫弶攴� 臧�瓴╈澑 $626.9024鞐愳劀 $639.3718 靷澊鞐� 毵る弰頄堨姷雼堧嫟. 氤搓碃霅� 毵る弰搿� 攴胳潣 歆侅爲 氤挫湢 欤检嫕鞚� 112,571.3016欤检棎靹� 83,311.3016欤茧 欷勳棃鞀惦媹雼�. 氤搓碃霅� 靾橂焿瓿� 臧�瓴╈潉 旮办鞙茧 毵る弰鞐� 霐半ジ 齑� 毵れ稖鞎§潃 鞎� $18.49 million鞛呺媹雼�. 鞝滌稖靹滌棎電� 霕愴暅 41,260欤茧ゼ 毵れ垬頃� 靾� 鞛堧姅 鞓奠厴 攵�鞐皜 02/14/2017攵�韯� 鞐瓣皠 5須� 攵勴暊搿� 頄夓偓臧�電ロ晿瓴� 霅橃棃雼る姅 鞏戈笁鞚� 韽暔霅橃柎 鞛堨姷雼堧嫟.

Jonathan Jay Mazelsky, pr茅sident-directeur g茅n茅ral et administrateur d'IDEXX Laboratories (IDXX), a d茅clar茅 une s茅rie d'op茅rations dat茅es du 08/06/2025. Il a acquis 29,260 actions en exer莽ant des options sur actions non qualifi茅es 脿 un prix d'exercice de $67.85 par action et a vendu le m锚me jour un total 茅quivalent de 29,260 actions ordinaires en plusieurs tranches 脿 des prix moyens pond茅r茅s rapport茅s entre $626.9024 et $639.3718 par action. Les ventes d茅clar茅es ont r茅duit ses participations directes de 112,571.3016 actions 脿 83,311.3016 actions. Sur la base des quantit茅s et des prix rapport茅s, le produit brut agr茅g茅 des ventes s'茅l猫ve 脿 environ $18.49 million. Le d茅p么t fait 茅galement r茅f茅rence 脿 une attribution d'option d'achat de 41,260 actions devenue exer莽able en cinq tranches annuelles 脿 partir du 02/14/2017.

Jonathan Jay Mazelsky, Pr盲sident und CEO sowie Direktor von IDEXX Laboratories (IDXX), meldete eine Reihe von Transaktionen datiert 08/06/2025. Er erwarb 29,260 Aktien durch Aus眉bung nicht qualifizierter Aktienoptionen zu einem Aus眉bungspreis von $67.85 je Aktie und verkaufte am selben Tag die entsprechende Gesamtanzahl von 29,260 Stammaktien in mehreren Tranchen zu den gemeldeten, nach Handelsvolumen gewichteten Durchschnittspreisen zwischen $626.9024 und $639.3718 je Aktie. Die gemeldeten Verk盲ufe verringerten seine Direktbeteiligung von 112,571.3016 Aktien auf 83,311.3016 Aktien. Basierend auf den gemeldeten St眉ckzahlen und Preisen belaufen sich die aggregierten Bruttoerl枚se aus den Verk盲ufen auf etwa $18.49 million. Die Einreichung verweist au脽erdem auf eine Optionszuweisung zum Kauf von 41,260 Aktien, die ab dem 02/14/2017 in f眉nf j盲hrlichen Tranchen aus眉bbar wurde.

Positive
  • Clear transparency: The Form 4 discloses all quantities, tranche-weighted prices and resulting ownership figures.
  • Substantial retained stake: After transactions, Mazelsky still directly owns 83,311.3016 shares.
Negative
  • Large insider sell: A total of 29,260 shares were sold on 08/06/2025, equal to the number acquired that day.
  • Significant gross proceeds: The disclosed sales generated approximately $18.49 million in aggregate proceeds, materially reducing reported direct holdings from 112,571.3016 to 83,311.3016 shares.

Insights

TL;DR: CEO exercised options and sold the acquired shares same day; he remains a significant shareholder with 83,311.3016 shares.

The Form 4 shows a same-day exercise of 29,260 optioned shares at $67.85 and matching sales that reduced direct beneficial ownership from 112,571.3016 to 83,311.3016 shares. From a governance perspective, the filing documents a material CEO transaction and preserves transparency by disclosing quantities, prices and resulting ownership. The continued holding of 83,311.3016 shares indicates ongoing direct ownership, while the disclosed option grant (41,260 shares exercisable in installments beginning 02/14/2017) remains on the record.

TL;DR: The reported sales of 29,260 shares generated roughly $18.49M in gross proceeds on 08/06/2025.

Using the per-tranche quantities and reported weighted-average prices in the filing, the ten sale tranches totaling 29,260 shares produced aggregate gross proceeds of approximately $18.49 million. The exercise price for the acquired shares was $67.85, documented in the filing. The transaction sequence鈥攅xercise followed by multiple sales the same date鈥攎aterially changed reported direct ownership levels and is fully itemized in the Form 4.

Jonathan Jay Mazelsky, presidente e CEO nonch茅 membro del consiglio di IDEXX Laboratories (IDXX), ha comunicato una serie di operazioni in data 08/06/2025. Ha acquisito 29,260 azioni esercitando opzioni su azioni non qualificate a un prezzo di esercizio di $67.85 per azione e nello stesso giorno ha venduto un totale corrispondente di 29,260 azioni ordinarie in pi霉 tranche a prezzi medi ponderati segnalati compresi tra $626.9024 e $639.3718 per azione. Le vendite riportate hanno ridotto le sue partecipazioni dirette da 112,571.3016 azioni a 83,311.3016 azioni. Sulla base delle quantit脿 e dei prezzi indicati, i proventi lordi aggregati delle vendite sono circa $18.49 milioni. Il deposito fa inoltre riferimento a una concessione di opzione per acquistare 41,260 azioni divenuta esercitabile in cinque rate annuali a partire dal 02/14/2017.

Jonathan Jay Mazelsky, presidente y director ejecutivo y miembro del consejo de IDEXX Laboratories (IDXX), inform贸 una serie de operaciones con fecha 08/06/2025. Adquiri贸 29,260 acciones al ejercer opciones sobre acciones no calificadas a un precio de ejercicio de $67.85 por acci贸n y ese mismo d铆a vendi贸 un total coincidente de 29,260 acciones ordinarias en varias tramos a precios medios ponderados reportados entre $626.9024 y $639.3718 por acci贸n. Las ventas notificadas redujeron sus tenencias directas de 112,571.3016 acciones a 83,311.3016 acciones. Seg煤n las cantidades y precios informados, los ingresos brutos agregados de las ventas ascienden aproximadamente a $18.49 millones. La presentaci贸n tambi茅n hace referencia a una concesi贸n de opciones para comprar 41,260 acciones que se volvi贸 ejercitable en cinco cuotas anuales a partir del 02/14/2017.

Jonathan Jay Mazelsky電� IDEXX Laboratories (IDXX)鞚� 須岇灔 瓴� CEO鞚挫瀽 鞚挫偓搿滌劀 08/06/2025鞚检瀽 鞚茧牗鞚� 瓯半灅毳� 氤搓碃頄堨姷雼堧嫟. 攴鸽姅 牍勳瀽瓴� 鞀ろ啞鞓奠厴鞚� 頄夓偓頃橃棳 欤茧嫻 頄夓偓臧�瓴� $67.85搿� 29,260欤茧ゼ 旆摑頄堨溂氅�, 臧欖潃 雮� 霃欖澕頃� 齑濌硠鞚� 氤错喌欤� 29,260欤茧ゼ 鞐煬 韸鸽灉旃橂 臧侁皝 氤搓碃霅� 臧�欷戫弶攴� 臧�瓴╈澑 $626.9024鞐愳劀 $639.3718 靷澊鞐� 毵る弰頄堨姷雼堧嫟. 氤搓碃霅� 毵る弰搿� 攴胳潣 歆侅爲 氤挫湢 欤检嫕鞚� 112,571.3016欤检棎靹� 83,311.3016欤茧 欷勳棃鞀惦媹雼�. 氤搓碃霅� 靾橂焿瓿� 臧�瓴╈潉 旮办鞙茧 毵る弰鞐� 霐半ジ 齑� 毵れ稖鞎§潃 鞎� $18.49 million鞛呺媹雼�. 鞝滌稖靹滌棎電� 霕愴暅 41,260欤茧ゼ 毵れ垬頃� 靾� 鞛堧姅 鞓奠厴 攵�鞐皜 02/14/2017攵�韯� 鞐瓣皠 5須� 攵勴暊搿� 頄夓偓臧�電ロ晿瓴� 霅橃棃雼る姅 鞏戈笁鞚� 韽暔霅橃柎 鞛堨姷雼堧嫟.

Jonathan Jay Mazelsky, pr茅sident-directeur g茅n茅ral et administrateur d'IDEXX Laboratories (IDXX), a d茅clar茅 une s茅rie d'op茅rations dat茅es du 08/06/2025. Il a acquis 29,260 actions en exer莽ant des options sur actions non qualifi茅es 脿 un prix d'exercice de $67.85 par action et a vendu le m锚me jour un total 茅quivalent de 29,260 actions ordinaires en plusieurs tranches 脿 des prix moyens pond茅r茅s rapport茅s entre $626.9024 et $639.3718 par action. Les ventes d茅clar茅es ont r茅duit ses participations directes de 112,571.3016 actions 脿 83,311.3016 actions. Sur la base des quantit茅s et des prix rapport茅s, le produit brut agr茅g茅 des ventes s'茅l猫ve 脿 environ $18.49 million. Le d茅p么t fait 茅galement r茅f茅rence 脿 une attribution d'option d'achat de 41,260 actions devenue exer莽able en cinq tranches annuelles 脿 partir du 02/14/2017.

Jonathan Jay Mazelsky, Pr盲sident und CEO sowie Direktor von IDEXX Laboratories (IDXX), meldete eine Reihe von Transaktionen datiert 08/06/2025. Er erwarb 29,260 Aktien durch Aus眉bung nicht qualifizierter Aktienoptionen zu einem Aus眉bungspreis von $67.85 je Aktie und verkaufte am selben Tag die entsprechende Gesamtanzahl von 29,260 Stammaktien in mehreren Tranchen zu den gemeldeten, nach Handelsvolumen gewichteten Durchschnittspreisen zwischen $626.9024 und $639.3718 je Aktie. Die gemeldeten Verk盲ufe verringerten seine Direktbeteiligung von 112,571.3016 Aktien auf 83,311.3016 Aktien. Basierend auf den gemeldeten St眉ckzahlen und Preisen belaufen sich die aggregierten Bruttoerl枚se aus den Verk盲ufen auf etwa $18.49 million. Die Einreichung verweist au脽erdem auf eine Optionszuweisung zum Kauf von 41,260 Aktien, die ab dem 02/14/2017 in f眉nf j盲hrlichen Tranchen aus眉bbar wurde.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
MAZELSKY JONATHAN JAY
(Last) (First) (Middle)
ONE IDEXX DRIVE
(Street)
WESTBROOK ME 04092
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
IDEXX LABORATORIES INC /DE [ IDXX ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
President and CEO
3. Date of Earliest Transaction (Month/Day/Year)
08/06/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 08/06/2025 M 29,260 A $67.85 112,571.3016(1) D
Common Stock 08/06/2025 S 1,095 D $626.9024(2) 111,476.3016 D
Common Stock 08/06/2025 S 1,525 D $628.272(3) 109,951.3016 D
Common Stock 08/06/2025 S 3,397 D $629.8228(4) 106,554.3016 D
Common Stock 08/06/2025 S 6,056 D $630.5935(5) 100,498.3016 D
Common Stock 08/06/2025 S 7,299 D $631.6065(6) 93,199.3016 D
Common Stock 08/06/2025 S 3,000 D $632.563(7) 90,199.3016 D
Common Stock 08/06/2025 S 3,526 D $635.1268(8) 86,673.3016 D
Common Stock 08/06/2025 S 1,822 D $636.1517(9) 84,851.3016 D
Common Stock 08/06/2025 S 880 D $636.8083(10) 83,971.3016 D
Common Stock 08/06/2025 S 660 D $639.3718(11) 83,311.3016 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Non-Qualified Stock Option (right-to-buy) $67.85 08/06/2025 M 29,260 (12) 02/13/2026 Common Stock 29,260 (13) 0 D
Explanation of Responses:
1. Includes 28.7090 shares purchased under the Issuer Employee Stock Purchase Plan on March 31, 2025 and June 30, 2025.
2. Represents the weighted average price of the shares sold ranging from a low of $626.585 to a high of $627.44 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
3. Represents the weighted average price of the shares sold ranging from a low of $627.72 to a high of $628.71 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
4. Represents the weighted average price of the shares sold ranging from a low of $629.14 to a high of $630.06 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
5. Represents the weighted average price of the shares sold ranging from a low of $630.14 to a high of $630.885 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
6. Represents the weighted average price of the shares sold ranging from a low of $631.26 to a high of $632.15 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
7. Represents the weighted average price of the shares sold ranging from a low of $632.41 to a high of $633.30 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
8. Represents the weighted average price of the shares sold ranging from a low of $634.66 to a high of $635.64 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
9. Represents the weighted average price of the shares sold ranging from a low of $635.66 to a high of $636.53 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
10. Represents the weighted average price of the shares sold ranging from a low of $636.66 to a high of $637.39 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
11. Represents the weighted average price of the shares sold ranging from a low of $639.235 to a high of 639.49 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
12. Grant of option to buy 41,260 shares of Issuer common stock that became exercisable in five annual installments beginning February 14, 2017.
13. Not applicable
Remarks:
/s/ Lily J. Lu, Attorney-in-Fact for Jonathan Jay Mazelsky 08/08/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source:

FAQ

What transactions did IDXX CEO Jonathan Mazelsky report on 08/06/2025?

He exercised 29,260 optioned shares at $67.85 per share and sold 29,260 common shares in multiple tranches the same day.

How many shares does Mazelsky own after the reported transactions?

Following the transactions he directly beneficially owns 83,311.3016 shares, down from 112,571.3016 shares before the sales.

What were the sale prices reported for the share tranches?

Reported weighted-average sale prices by tranche range from $626.9024 to $639.3718 per share across the disclosed sales.

What were the aggregate proceeds from the sales?

Based on the filing鈥檚 quantities and reported weighted-average prices, aggregate gross proceeds are approximately $18.49 million.

Does the filing reference other option grants?

Yes. The filing notes a grant of options to buy 41,260 shares that became exercisable in five annual installments beginning 02/14/2017.
Stock IDXX logo
IDEXX Laboratories

NASDAQ:IDXX

IDXX Rankings

#290 Ranked by Market Cap
N/A Ranked by Dividends

IDXX Latest News

Sep 2, 2025
IDEXX Laboratories to Participate in Morgan Stanley 23rd Annual Global Healthcare Conference
Aug 4, 2025
IDEXX Laboratories Announces Second Quarter Results
Jul 30, 2025
IDEXX Releases 2024 Corporate Responsibility Report, Highlighting Progress Against Its Goals
Jul 10, 2025
IDEXX Laboratories Elects Joseph L. (Jay) Hooley to Board of Directors
Jun 24, 2025
IDEXX Laboratories to Release 2025 Second Quarter Financial Results

IDXX Latest SEC Filings

Sep 4, 2025
[Form 4] Idexx Laboratories Inc Insider Trading Activity
Sep 3, 2025
[Form 4] Idexx Laboratories Inc Insider Trading Activity
Sep 3, 2025
[Form 4] Idexx Laboratories Inc Insider Trading Activity
Aug 26, 2025
[Form 4] Idexx Laboratories Inc Insider Trading Activity
Aug 22, 2025
[144] Idexx Laboratories Inc SEC Filing

IDXX Stock Data

50.72B
79.45M
0.68%
97.51%
3.1%
Diagnostics & Research
In Vitro & in Vivo Diagnostic Substances
United States
WESTBROOK